MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Mabworks Biotech Co., Ltd.
About this trial
This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).
Eligibility criteria
Qualifiers
Adult patients, >=18 years of age;
Patients with either histologically documented CD20-positive MZL or FL, WHO grade 1, 2 or 3a
Evidence of progression or lack of response following at least 1 prior treatment
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Disqualifiers
Evidence ongoing transformation into aggressive NHL
Central nervous system lymphoma
Patients with progressive multifocalleukoencephalopathy (PML)
Prior use of any antibody therapy(except for Rituximab ) within 3 months of study start
Trial design
Treatments tested in this trial
- Recombinant Humanized Monoclonal Antibody MIL62 Injection
- Lenalidomide
Treatment groups
53 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov